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Abstract 
 Background The use of decision support interventions in the context of decisions about 
trial participation is an emergent field.  There is a lack of evidence about what 
information is deemed important to support decisions about informed consent for 
clinical trials, and whether different groups agree on the information for inclusion.   
 Purpose The overall objective was to determine the items which different stakeholder 
groups viewed to be important for inclusion in a decision support tool when making 
decisions about clinical trial participation; with a view to use these as a framework for 
developing decision support tools in this context.  This is the first study to have 
addressed this issue. 
 Methods A modified Delphi method was used to determine agreement on importance 
of items.  The ‘stakeholder’ panel was made up of 49 individuals from 5 groups: 11 
trialists; 6 research nurses; 7 ethics committee chairs; 9 decision support experts and 16 
patients (9 trial experienced and 7 trial non-experienced).  Two rounds of rating were 
completed. Items with a median of 7-10 with ≥65% of any one group (from aggregate 
ratings) in agreement were considered important for inclusion. 
 Results The stakeholder panel achieved consensus on the majority of items included 
(60/66), agreeing that these were important for inclusion in a decision support tool for 
trial participation. These included items covering: information about trial participation 
and standard care; information on the likelihood of receiving different treatments; 
information to help patients’ determine what matters most to them; ensuring the 
information is balanced; guidance on how to make a decision; disclosure of any conflicts 
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of interest; using plain language in the tool and guidance on the decision support 
development process. Some areas of divergence amongst the panel were also identified 
relating to the use of patient stories. 
 Limitations Selection bias may be a limitation in this study due to the manner in which 
the participants were invited to take part and therefore the representativeness, and 
reproducibility with another group of stakeholders, may differ. 
 Conclusions Agreement was obtained on a number of items, which we recommend 
should be used as a framework to develop useful tools to support decision making about 
participation in clinical trials. 
(word count 358) 
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Introduction 
The process of gaining informed consent for participation in clinical trials has been 
established as a mechanism to protect potential participants against undue harm and aims 
to allow participants to make informed and autonomous choices about whether or not to 
participate in research trials.1  
When invited to participate, potential participants are currently provided with a patient 
information leaflet (PIL) that contains required information about the trial and may form the 
basis of their decision about participation.2  It is also likely that a member of the research 
team will engage in a conversation with the participant to answer any questions or concerns 
the participant may have before their informed consent is sought.  Despite this process, 
there is evidence that some trial participants, both those considering participation and 
those who are actively enrolled, fail to understand key components of the trial processes 
and/or rationale, putting into question the adequacy of the current informed consent 
process.3, 4, 5, 6  
Several studies have investigated the effects of changing the structure of the information 
provided during the informed consent process for clinical trials mostly with the aim of 
improving understanding or recruitment.3, 6, 7  Yet to date, none of these studies have been 
able to determine optimal strategies, or outcome measures, in this context.  Moreover, a 
recent review highlighted that little empirical evidence exists with regard to what 
information potential participants want to know when considering trial participation. 8    
 
Although provision of fact-based information is an important step for decision making, other 
influences on the process have been shown to be important.4, 9, 10  For example, one study 
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found participants who are less satisfied with their decision to participate feel significant 
regret about their decision.11  This provides further evidence that trial participants 
potentially require greater support during the decision making process to ensure that any 
decision is right for them.  
There is an established evidence base in the treatment and screening decision making field 
that has investigated ways of facilitating and improving decisions.12  This work has led to the 
development of tools (“decision aids”) to support decision making, 13  These decision aids 
are designed to promote a specific, deliberative process of decision making allowing people 
to make explicit choices about options and clarify what domains are important to them.  .13  
There is  evidence to show that decision aids are effective at improving decision making in a 
variety of clinical contexts.13  and preliminary studies have begun to explore their potential 
role  in the informed consent process for clinical trials .14, 15, 16, 17  
The International Patient Decision Aid Standards (IPDAS) is a set of quality criteria for 
decision aids.18  They focus not only on information provision, but also on aspects of the 
process of decision making; as such the application of the IPDAS principles may be a 
potential way to improve the decision-support process for  informed consent for clinical 
trials.   
The main objective of this study, therefore, was to determine the items (informational and 
procedural) which different stakeholder groups viewed to be important for inclusion in a 
decision support tool when making decisions about clinical trial participation; with a view to 
use these as a framework for developing decision support tools in this context.  This is the 
first study to have addressed this issue. 
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Methods 
The Delphi method seeks to gain consensus of opinion from a pre-selected group of 
stakeholders, often experts in the field, by using a series of self-completed questionnaires in 
‘rounds’ of responses.19  The method can be used as a means of achieving consensus but 
also exploring divergence between stakeholder.  As the panel of stakeholders do not meet, 
individuals can express their opinions without being influenced by others. This study 
employed a ‘modified’ Delphi, in that the items generated for inclusion were generated 
through a systematic review process and not through the traditional interviews and 
discussion with the stakeholder group.19, 20  Modified Delphi studies have been conducted 
by other health services researchers.21, 22 
 
Establishing the Delphi panel 
Purposive stratified sampling was used to establish the Delphi panel.  We considered 5 
stakeholder groups to be relevant for this study: trialists, research nurses, ethics committee 
chairs, decision aid researchers and patients, who were further sub-divided into a trial 
experienced (defined by taking part in at least 1 clinical trial) and trial non-experienced 
group.  These groups were deemed important as they may be involved in the design, 
development, delivery, ethical review or be potential users of this type of decision support 
tool.  Potential participants were invited to take part through email distribution lists 
(trialists: UK Clinical Research Collaboration Trial Managers listserv; research nurses: 
Scottish Research Nurse and Coordinators Network listserv; ethics committee chairs: 
National Research Ethics Service committee chair listserv; decision aid researchers: Society 
for Medical Decision Making Shared Decision Making Interest Group listserv; and patients: 
National Institute for Health Research Patient and Public Involvement listservs)  and were 
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asked to respond directly to the lead researcher (KG) if interested in participating.  
Individual participants were anonymised, in that they did not know the identities of the 
other individuals in the group or specific answers that any other individual gave. 
 
Delphi item development 
We searched Medline and EMBASE (1974-2010) using key words and terms including 
‘informed consent’, ‘clinical trial’, ‘randomisation’, and ‘guideline’ to identify relevant 
guidelines on informed consent for clinical trials.  The search was supplemented with known 
guidelines on the topic from clinical or regulatory bodies such as the General Medical 
Council, the Research Governance Frameworks, and guidelines produced by the National 
Research Ethics Service (NRES).  Data regarding information or process requirements for 
informed consent for clinical trials was abstracted from the identified guidelines.  The 
abstracted data were compared to items included in the IPDAS standards, which were 
relevant for decisions about trial participation, and topics developed into items for inclusion 
in the questionnaire.  All identified items were included in the questionnaire.  Any items 
with considerable overlap were included as one item.  The questionnaire was piloted with 
researchers (n=10) and patients (n=5)  
Round One 
The final questionnaire contained 66 items divided into 10 sections, which were based on 
the results from the systematic review and supplemented with items from the IPDAS 
(questionnaire available on request).  We also collected some information on demographics 
of respondents in order to describe the sample.  A covering letter was included that 
explained: the purpose and aim of the Delphi study, including the proposal that the items 
would inform development of an intervention to replace existing patient information 
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leaflets (items included in the questionnaire covered all existing ethical standards for 
patient information for clinical trial participation); how the items had been developed; and 
instructions on how to rate using the likert scale.  Participants were given the option of 
receiving the questionnaire by post or email, with the email option providing an electronic 
version of the questionnaire for completion. 
 
Each of the 10 sections was prefixed by a short introduction describing the purpose of that 
particular section and participants were asked to rate the importance of each individual 
item for inclusion in a decision support tool for trial participation.  Importance was rated on 
a scale of 1 = not important to 10 = very important, or no opinion, (figure 1).  A 10 point 
scale was chosen as it may limit the bias of central tendency found in using scales with odd 
values.  There is evidence that using a 10 point scale, over a 5 or 7, should introduce more 
variability (Dawes et al).  Participants could also include any additional comments in a free 
text box at the end of each section.  Two rounds of rating were completed.  
 
Round Two 
Three new items were included in the Round Two questionnaire based on comments 
received from round one  Consistent with the Delphi method, second round participants 
were presented with feedback information from round one.  Feedback of both qualitative 
and quantitative data between rounds has been recommended.23  For each item, feedback 
included a frequency distribution of the group scores, the median and interquartile range, 
individual participant’s previous scores and a summary of the qualitative comments for each 
section (Figure 1).  The quantitative data allowed participants to reflect on their own 
position relative to the rest of the group.  The qualitative comments made during round one 
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were summarised to include both positive and negative attitudes expressed in round one to 
provide a contextual background against which participants could base their ratings.   
Email reminders, using text suggested by Sinha et al (2011),24 were sent to non-responders 
in each round  Final data on importance of items presented in this paper are based on 
second round median ratings only.   
 
Definition of ‘consensus’ 
As there is no general agreement on the level of predetermined measures of consensus, we 
defined agreement as   Although some researchers argue that there has to be 100% 
agreement for consensus to be achieved, it is more common and acceptable that consensus 
is reached when the majority of experts agree on items.25  Agreement on items was defined 
as any item for which 65% or more of any individual stakeholder group were in agreement.  
Agreement was first investigated across all respondents, then at an individual stakeholder 
group level.  Items were classified as demonstrating ‘agreement’ as follows: median of 7 to 
10 important and required for inclusion; median of 5 to 6 undetermined and require further 
follow up; median of 1-4 not important and not required for inclusion.  Disagreement on 
items was defined by 30% or more ratings, of any individual group, being scored as 1-4 and 
30% or more of the ratings being scored as 7-10. Items which exhibited disagreement were 
deemed as requiring further follow up.  Any items that did not fulfil these decision rules 
were classed as equivocal and requiring further follow up. 
 
Research governance requirements 
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This study was approved by the North of Scotland Research Ethics Committee (REC 
Reference Number 09/S0802/105) and NHS Grampian Research and Development 
department (Reference Number 2009HS002).  
 
 
Results 
Stakeholder panel 
Table 1 describes the participants’ response rate in the first and second rounds.  We 
approached people who expressed an interest to participate in the Delphi process in 
response to the email invitation. (Of those who expressed an interest, 60/66 (92%) 
completed round one and 49/60 (82%) completed both rounds of rating.   Table 2 details 
the characteristics of the participants who completed both rounds.  There was no significant 
difference in the number of individuals in stakeholder groups in the final sample.  The 
participants had a varied distribution of experience with decision support tools, with 53% 
having no previous experience, 29% having limited experience and 18% being experienced. 
 
Consensus across items 
The median ratings achieved for each item after two rounds of rating are reported in 
supplementary information (Table S1).  Of the 69 items, agreement was reached, at an 
entire group level, on 53 items with 9 given an overall median of 8, 18 a rating of 9 and 26 a 
rating of 10.  These 53 items were encompassed by the following sections: ‘The 
development process’; ‘Providing information about trial participation and standard care’; 
‘Presenting information on the likelihood of receiving different treatments’; ‘Determining 
what matters to patients’; ‘Decision guidance’; ‘Disclosing conflicts of interest’; ‘Balancing 
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the presentation of options’; and ‘Using plain language’.   Nine items had equivocal ratings 
in that they did not fulfil the criteria for agreement or disagreement at the entire group 
level (Box 1).  .  However, each of these items showed agreement on importance within at 
least one of the individual ‘stakeholder’ group and as such were deemed important for 
inclusion according to the predefined decision rules.    Disagreement was exhibited, at a 
whole group level, on 6 items, which were contained within one main section; using stories 
from other participants (41, 42, 43, 45) and two additional items; item 56. Readability levels 
are reported; and item 65. The date the decision support tool was produced is reported.  
However, agreement was shown to be present by at least one stakeholder group for all of 
these items (supplementary information Table S2).  Therefore, no items exhibited 
disagreement within all individual groups, as defined by the pre-stated decision rules. 
 
Variability between stakeholder groups 
Although many of the items exhibited agreement at an entire group level, specific 
stakeholder groups showed more variation than others on some items (for example, items 
12. The decision support tool presents information about the advantages/benefits of non-
participation and 13. The decision support tool presents information about the 
disadvantages/harms of non-participation). Also, the items that were deemed as ‘equivocal’ 
by the entire group, (i.e. no agreement or disagreement on importance), illustrated 
variability between stakeholder groups. Of particular interest, was that some of these items 
clustered in the ‘Basing included information on up to date scientific information’ section.  
Five out of the six items were shown to be equivocal at the entire group level with the 
remaining item showing disagreement.     
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The section on ‘Using stories from other participants’ exhibited noteworthy variability and 
highlighted areas of divergence between the groups.  This section contained 5 items (41. 
The decision support tool provides stories of other participants’ experiences of deciding to 
participate, or not, in a trial; 42. The decision support tool provides stories that represent a 
range of experiences (positive and negative) of taking part, or not, in a trial; 43. The decision 
support tool explains the processes used to select these stories; 44. The decision support tool 
explains how experts reviewed the information contained within the stories; and 45. The 
decision support tool states that the participants gave informed consent to include their 
stories), which were rated as 6, 6, 5, 4, and 7, respectively, by the group and all exhibited 
considerable distribution across the interquartile ranges (minimum 6 point difference).  
However, the stakeholder groups differed in their median ratings with the trial experienced 
patient group agreeing that 41, 42, 43, and 45 were important items (rated 9, 8, 8, 9 
respectively) and the research nurse group also agreeing that item 45 was important (rated 
9) (supplementary information Table S2).  Yet, trialists and ethics committee chairs deemed 
these items less important (trialists rated 3, 4, 2, 3 and ethics committee chairs 2, 2, 5, 3 for 
items 41, 42, 43, and 45).  Several of the comments provided in the free text boxes offered 
some insight into the variability exhibited for this item (Box 1).   
Overall, irrespective of agreement or disagreement on items, trialists and ethics committee 
chairs tended to rate items less important compared to the other groups.  For example, at a 
group level a total of 28 items were rated as a median of 10, whereas the trialist group and 
ethics committee chair group scored only 18 and 15 items a median of 10, respectively 
(Table 3).  These two groups were also the only groups to score any items a median of 3 or 
2. In Contrast, patients, in particular the trial experienced patient group, rated more items 
of higher importance compared to other groups, as they scored a total of 49 items a median 
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of 10 and scored no item less than 6 (Table 3).  Decision aid researchers generally rated 
items of higher importance, not rating any item less than a 5 (Table 3).  No individual group 
produced a median of 1 for any item. 
 
Discussion 
Principal findings 
This is the first study, to our knowledge, to use a stakeholder consensus based approach to 
determine the importance of items for inclusion in a potential decision support tool to 
facilitate decisions about participation in clinical trials.  The Delphi process determined that 
the majority of items (53/69, 77%) were deemed important by all  stakeholders for inclusion 
in such a tool.  The Delphi also revealed areas of divergence between groups, which 
highlight areas for further research.  Where stakeholder groups’ ratings differed, trial-
experienced patients and decision aid researchers tended to give higher ratings where as 
trialists and research ethics committee chairs tended to rate items lower. 
As with the Delphi study to generate the IPDAS,18 our study identified the use of patient 
stories as a contentious area for inclusion in decision support tools for trial participation.  
Several of the comments, from the decision aid researchers, ethics committee chairs and 
trialists,  illustrated concerns about using this type of information due to the lack of 
empirical evidence of the effect of patient stories on decision making and the caution that 
their use may potentially bias some decisions depending on how stories are selected and 
presented, which has also been discussed in the literature.26  Yet  patients and research 
nurses largely felt this information was important and would be helpful in such a tool.  The 
impact of this information on decision making for trial participation requires evaluation.   
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Three sections which have been previously shown to be important for inclusion in decision 
support tools,18 but not core to informed consent guidance, were strongly endorsed by the 
group when considering their importance for inclusion in a decision support tool for trial 
participation.  These items are: a) presenting information on the likelihood of receiving 
different treatments (patient information leaflets provide information on the chance of 
receiving a treatment based on random allocation, but the guidance does not detail specify 
how to present and format  probabilistic information to assist understanding of risk); b) 
determining what matters to patients; and c) decision guidance.  “Decision guidance”, which 
is a structured approach designed to help patients think about the best option for them (it 
can include worksheets or a structured set of questions for a person to address), might 
usefully be prioritised for future research.  These sections are not currently included in 
informed consent guidance yet there is evidence in the literature that provides further 
impetus to consider their inclusion. 14, 15,2719   
Strengths and limitations 
The primary strength of this study is that it is the first, to our knowledge, that has 
empirically addressed the issue of importance of information and decision support 
processes in a tool for trial participation using a consensus based approach across a range of 
stakeholders. A further strength of the study was the high response rates achieved across 
both rounds with little attrition between rounds (responses of 92% and 82% for round 1 and 
2 respectively).  This is encouraging as, unlike other methods, Delphi requires a continued 
commitment from participants as they are questioned repeatedly about the same topic 
using a slightly modified questionnaire..  Moreover, the method explicitly addresses the 
interests and involvement of several key stakeholder groups.  Each of these groups was 
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given equal weighting during the analysis so as to retain the representativeness in the final 
item set. 
A recognised concern with the Delphi method is the selection of the stakeholder panel as 
there is no explicit guidance on sampling techniques for this purpose.28  It is likely selection 
bias may be a limitation in this study due to the manner in which the participants were 
invited to take part and therefore the representativeness, and reproducibility with another 
group of stakeholders, is not assured.  However it is accepted that having a heterogeneous 
group, where stakeholders are drawn from varied backgrounds, can ensure a wider 
knowledge base and may allow for consideration of different perspectives.29  As such, our 
multidisciplinary panel may help to balance any bias introduced through sampling.  Lastly, 
respondents were not explicitly asked to rank importance of Delphi items whilst considering 
contextual factors such as time, cost, resource, etc, all of which may have influenced their 
perceived importance when faced with making a trade-off.  However, some of these factors, 
such as time, were identified in the open comments section of the questionnaire by some 
respondents.  Therefore, it could be deduced that the Delphi participants considered such 
external factors implicitly when making their determinations of items of importance for 
inclusion. 
 
Results in context 
To our knowledge no formally published data exist on eliciting stakeholder consensus on 
items important to facilitate decisions about clinical trial participation. The Delphi method 
was the appropriate method to use to answer this research question for its value in 
extracting and combining the views of many stakeholders.  A further strength of the method 
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was the ability to analyse the data according to stakeholder group so as to reflect the 
priorities of individual groups as well as the entire group, in context.   
The results may have implications for those recruiting potential participants to clinical trials 
as they suggest ways of improving the presentation of information, provide methods to 
allow personalisation of the information for the individual and provide suggestions for 
guidance through the decision. The purpose of the aggregated list is not to be prescriptive 
but more to provide potential solutions to improve the quality of decision making and 
better support the process in a trial context.  However, these potential solutions require 
further analysis and empirical evidence to warrant use in practice. 
Future research could explore the prioritisation of the items agreed as important by asking 
participants to rank the most important items, or sections, to give an indication of priority.  
Further work should also explore the lack of group consensus on specific items, such as the 
use of patient stories, amongst the different stakeholder groups. 
 
Conclusions 
This study has used a robust approach to develop stakeholder consensus on items that 
could be included in decision aids for trial participation.  We recommend that this list forms 
the framework to inform any future studies on the development of tools to support decision 
making about participation in a clinical trial.  These tools should then be evaluated, against 
existing methods, for their ability to support the decision making process for clinical trial 
participation on a range of outcomes for decision quality and trial methodology. 
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